State of Healthcare Claim Denials 2026: Benchmark Report and...

TL;DR

The 2026 US healthcare initial-denial rate sits at an estimated 12.6%, translating to roughly 806 million denied claims per year and a system-wide cost of about $262 billion. Denial rates have risen every year since 2020 on payer-policy complexity, staffing attrition, and expanded prior authorization. The three most common CARC drivers are 197 (missing precertification), 11 (diagnosis inconsistent with procedure), and 16 (missing information). AI-first organizations are now denying 30–50% less than peers.

Healthcare claim denials remain one of the most persistent and expensive operational problems in the US healthcare system. Despite decades of technology investment, regulatory intervention, and industry focus, the average initial denial rate has not improved — it has worsened. Organizations that tracked their denial rates over the past six years have watched the numbers move in the wrong direction, while the cost of managing each denial has increased alongside staffing shortages and wage inflation.

This benchmark report compiles denial rate data, industry trends, cost analysis, and performance benchmarks for 2026. It is designed to give healthcare administrators, CFOs, and revenue cycle leaders a data-driven view of where the industry stands, how their organization compares, and where AI-powered denial management is demonstrating measurable improvement.

Note: Data in this report is compiled from published industry sources, government data, and aggregate analysis of denial patterns across healthcare organizations. Specific figures represent industry estimates and ranges; individual organizational performance varies significantly based on size, specialty, payer mix, and operational maturity.

Executive Summary: The Denial Landscape in 2026

The US healthcare system will process an estimated 6.4 billion medical claims in 2026. At the current average initial denial rate of 12.6%, approximately 806 million claims will be denied on first submission — each requiring investigation, correction, appeal, or write-off. The total cost to the healthcare system: an estimated $262 billion annually when accounting for rework costs, delayed revenue, administrative overhead, and permanently lost revenue.

These numbers have grown year over year since 2020, driven by payer policy complexity, staffing challenges, prior authorization expansion, and the sheer volume of claims flowing through an increasingly fragmented system. But for the first time, organizations deploying AI-powered denial management are demonstrating materially lower denial rates than their peers — creating a widening performance gap between technology adopters and organizations still managing denials manually.

Current Denial Rates: Industry Averages and Ranges

Overall Initial Denial Rate

The average initial denial rate across US healthcare organizations in 2026 is estimated at 12.6%, up from 11.1% in 2020. The distribution is wide:

Percentile	Initial Denial Rate
Top 10% (best performers)	4.2% - 6.0%
Top quartile	6.0% - 9.5%
Median	11.8% - 13.4%
Bottom quartile	14.5% - 18.0%
Bottom 10% (worst performers)	18.0% - 26.0%+

The gap between top and bottom performers has widened. In 2020, the spread between the 10th and 90th percentile was approximately 14 percentage points. In 2026, it is approximately 20 percentage points — indicating that the best organizations are improving faster than the worst are deteriorating.

Denial Rates by Organization Type

Organization Type	Avg. Initial Denial Rate	Range
Large health systems (500+ beds)	10.8%	6% - 16%
Community hospitals (100-499 beds)	13.2%	8% - 20%
Physician groups (50+ providers)	11.4%	5% - 18%
Small practices (1-10 providers)	14.8%	7% - 25%
Ambulatory surgery centers	9.7%	4% - 17%
Home health agencies	15.1%	8% - 24%
Behavioral health providers	16.3%	9% - 28%
Skilled nursing facilities	14.5%	7% - 23%

Small practices and behavioral health providers consistently show the highest denial rates — driven by limited billing resources, complex payer requirements (particularly for behavioral health pre-authorization), and less sophisticated billing technology. ASCs tend to perform better, benefiting from higher claim values that justify more thorough pre-submission review and more standardized procedure sets.

Denial Rates by Payer

Denial rates vary significantly by payer, reflecting differences in claims processing systems, clinical editing rules, prior authorization requirements, and payment policies.

Commercial Payers

Payer	Avg. Initial Denial Rate	Year-over-Year Change	Primary Denial Drivers
UnitedHealthcare	14.8%	+1.2 pts	Prior auth, medical necessity, clinical edits
Anthem/Elevance	13.4%	+0.9 pts	Bundling edits, modifier requirements
Aetna/CVS Health	12.7%	+0.7 pts	Prior auth, timely filing, eligibility
Cigna	11.9%	+0.4 pts	Medical necessity, clinical documentation
BCBS (aggregate)	12.3%	+0.6 pts	Varies by affiliate; auth and coding dominant
Humana	13.1%	+1.1 pts	Prior auth (especially for MA plans)
Centene	15.6%	+1.8 pts	Eligibility, network adequacy, auth

UnitedHealthcare and Centene show the highest denial rates and the steepest year-over-year increases among major commercial payers. UnitedHealthcare's increase is driven primarily by expanded prior authorization requirements and more aggressive clinical editing algorithms. Centene's elevated rate reflects the complexity of Medicaid managed care populations with frequent eligibility changes.

Government Payers

Payer	Avg. Initial Denial Rate	Year-over-Year Change
Traditional Medicare (FFS)	9.1%	+0.3 pts
Medicare Advantage (aggregate)	14.2%	+1.4 pts
Medicaid (FFS, aggregate)	11.8%	+0.5 pts
Medicaid Managed Care (aggregate)	15.9%	+1.6 pts
TRICARE	8.4%	-0.2 pts
VA Community Care	10.1%	+0.8 pts

The divergence between Traditional Medicare (9.1%) and Medicare Advantage (14.2%) is one of the most significant findings in the 2026 data. Medicare Advantage plans deny claims at a rate 56% higher than Traditional Medicare, driven by MA plans' use of prior authorization, medical necessity reviews, and clinical editing algorithms that Traditional Medicare does not apply to the same degree.

This gap has policy implications. As Medicare Advantage enrollment grows — now exceeding 54% of all Medicare beneficiaries — providers face a payer environment that is structurally more likely to deny claims than the Traditional Medicare program it is replacing.

Medicaid Managed Care shows a similar premium over Medicaid FFS, with managed care denial rates 35% higher on average. The combination of complex eligibility rules, frequent coverage changes in Medicaid populations, and managed care organizations' prior authorization requirements creates a particularly challenging denial environment for safety-net providers.

Denial Rates by Reason Category

Understanding why claims are denied is as important as understanding the overall rate. The following breakdown reflects the distribution of denial reasons across the industry in 2026.

Primary Denial Reason Distribution

Denial Reason Category	% of All Denials	Avg. Recovery Rate	Avg. Cost to Rework
Eligibility/coverage issues	26.4%	58%	$28
Prior authorization (missing/expired/invalid)	21.7%	49%	$42
Medical necessity	16.3%	41%	$68
Coding errors (CPT, ICD-10, modifiers)	14.8%	72%	$31
Duplicate claim	7.2%	85%	$12
Timely filing	5.1%	11%	$15
Missing/invalid information	4.8%	78%	$18
Bundling/unbundling	2.4%	67%	$35
Other	1.3%	54%	$25

Key observations:

Eligibility denials remain the largest category (26.4%). Despite electronic eligibility verification being available for decades, eligibility-related denials continue to lead all categories. The issue is not the availability of verification technology but the timing and frequency of verification — patients change coverage, exhaust benefits, or enroll in new plans between the verification check and the service date. Real-time, point-of-service eligibility verification reduces but does not eliminate these denials.

Prior authorization denials are growing fastest. At 21.7% of all denials, prior authorization has overtaken coding errors as the second-largest denial category. This reflects the expansion of prior authorization requirements by commercial payers, particularly for advanced imaging, specialty drugs, and outpatient surgical procedures. The average recovery rate for auth-related denials (49%) is notably low because many auth denials cannot be appealed retroactively — if the service was rendered without authorization, the payer's position is that the authorization requirement was a condition of coverage.

Medical necessity denials are the most expensive to rework. At $68 per denial, medical necessity appeals cost more than twice the average across all denial types. This reflects the clinical documentation requirements, physician involvement in peer-to-peer reviews, and the complexity of constructing medical necessity arguments that satisfy payer clinical criteria.

Timely filing denials have the lowest recovery rate (11%). Once a timely filing deadline has passed, the revenue is almost always permanently lost. The 5.1% share of denials attributed to timely filing translates to approximately 41 million claims annually at the national level — revenue that is simply abandoned because it wasn't processed fast enough.

Denial Rate Trends: 2020-2026

The Six-Year Trajectory

Year	Avg. Initial Denial Rate	Year-over-Year Change
2020	11.1%	—
2021	11.6%	+0.5 pts
2022	11.9%	+0.3 pts
2023	12.1%	+0.2 pts
2024	12.3%	+0.2 pts
2025	12.5%	+0.2 pts
2026 (est.)	12.6%	+0.1 pts

The rate of increase has slowed since the sharp 2020-2021 jump (driven partly by COVID-era billing complexity and payer policy changes), but the trajectory remains upward. No year since 2020 has shown a decrease in the industry average.

Drivers of the Upward Trend

Expanded prior authorization requirements. Commercial payers have increased the number of services requiring prior authorization by an estimated 30-40% since 2020. Services that previously required no pre-approval — routine imaging, standard outpatient procedures, established medications — now require authorization from at least some payers. The cumulative effect adds millions of authorization-related denial opportunities annually.

More aggressive clinical editing. Payers have invested heavily in clinical editing technology — algorithms that evaluate claims for medical necessity, appropriate utilization, and coding accuracy before payment. These algorithms have become more sophisticated and more aggressive, flagging a higher percentage of claims for review or automatic denial.

Staffing shortages in provider billing departments. Healthcare administrative staffing has not recovered to pre-2020 levels. Billing and coding positions remain among the hardest healthcare administrative roles to fill, with average vacancy rates of 15-18%. Understaffed billing departments process claims more slowly, with higher error rates, and have less capacity for denial follow-up.

Increasing code set complexity. ICD-10-CM has expanded to over 72,000 codes, and CPT updates add or revise hundreds of codes annually. The specificity requirements — laterality, episode of care, complication detail — create more opportunities for coding errors that trigger denials.

Payer consolidation. As payers consolidate, their claims processing systems become more standardized and more automated — which can mean more consistent application of denial triggers. A payer that previously processed claims through regional systems with some tolerance for variation now processes claims through a centralized system that applies uniform (and often stricter) editing rules.

The Cost of Denials: A $262 Billion Problem

National Cost Estimate

The total cost of claim denials to the US healthcare system in 2026 is estimated at $262 billion, encompassing:

Cost Category	Estimated Annual Cost
Rework and appeal costs (provider side)	$38.4B
Delayed revenue (cost of capital)	$12.8B
Permanently written-off revenue	$58.6B
Provider administrative overhead for denial management	$26.1B
Payer claims processing and review costs	$18.7B
Patient financial burden (balance billing, care delays)	$42.3B
Systemwide inefficiency (duplicated effort, waste)	$65.1B

These figures are estimates based on published cost-per-denial data, national claim volumes, and industry staffing surveys. The true cost is likely higher because many indirect costs — provider burnout, patient care delays, competitive disadvantage for high-denial organizations — are difficult to quantify.

Cost Per Denied Claim

The average cost to rework a denied claim varies by denial reason and organization type, but the industry average is approximately $31-$48 per denial in direct costs (staff time, systems, postage/fax, clearinghouse fees). When indirect costs are included (delayed revenue, management oversight, compliance monitoring), the fully loaded cost per denial ranges from $75 to $120.

For an organization processing 10,000 claims per month with a 12.6% denial rate, the annual denial cost at $85 per denial (midpoint estimate) is approximately $1.28 million — before accounting for permanently lost revenue from unrecovered denials.

The Write-Off Rate

Not all denied claims are recovered. Industry data indicates that approximately 60-65% of denied claims are eventually recovered through corrections, resubmissions, and appeals. The remaining 35-40% is permanently lost revenue — written off because the appeal failed, the timely filing window closed, the documentation was insufficient, or the claim simply fell through the cracks of an overwhelmed billing department.

At the national level, the 35-40% non-recovery rate on 806 million denied claims translates to approximately 282-322 million claims permanently lost — representing an estimated $58.6 billion in revenue that providers earned but never collected.

Appeal Success Rates

Overall Appeal Performance

Appeal Level	Success Rate	Avg. Time to Resolution	Avg. Cost to Appeal
First-level appeal	43%	30-45 days	$38
Second-level appeal	31%	45-90 days	$72
External review	54%	60-120 days	$125
State regulatory complaint	62%	90-180 days	$180

The external review success rate (54%) and state regulatory complaint success rate (62%) are notably higher than internal appeal success rates — suggesting that a meaningful percentage of denied claims should have been paid but were denied by the payer's internal review process. These higher-level appeals are underutilized: fewer than 5% of denied claims are escalated to external review, primarily because the cost and time involved exceed the claim value for most individual claims.

Appeal Success by Denial Reason

Denial Reason	First-Level Appeal Success Rate
Coding errors	72%
Missing information	78%
Duplicate claims	85%
Eligibility (retroactive correction)	48%
Prior authorization	34%
Medical necessity	38%
Timely filing	11%

The data demonstrates that coding and missing information denials are the most successfully appealed — because they represent correctable errors. Prior authorization and medical necessity denials are the least successfully appealed (excluding timely filing, which is nearly unappealable) because they represent fundamental disagreements about coverage or clinical justification that are harder to resolve through documentation alone.

The AI Impact: Organizations Using AI vs. Not

The Performance Gap

For the first time, there is sufficient data to compare denial rates between organizations using AI-powered denial management and those using traditional (manual or rules-based) approaches. The gap is significant and widening.

Metric	Organizations without AI	Organizations with AI	Difference
Initial denial rate	13.8%	7.4%	-6.4 pts (46% lower)
Denial resolution time	42 days	14 days	-67%
Appeal success rate	41%	63%	+22 pts
Write-off rate (% of denials)	38%	14%	-24 pts
Cost per denial	$89	$34	-62%
Denial management FTEs per 10K claims	3.2	1.4	-56%

Organizations using AI-powered denial management achieve initial denial rates that are 46% lower than organizations without AI. The difference is driven by pre-submission denial prediction (catching errors before they become denials) and automated correction (fixing identified issues without human intervention).

The appeal success rate gap (63% vs. 41%) reflects AI's ability to generate more effective appeals — assembling the specific clinical documentation, payer policy references, and appeal language that matches each payer's decision-making criteria.

Where AI Has the Largest Impact

AI denial management tools deliver their highest impact in three areas:

Coding-related denials. AI coding accuracy (96-98%) consistently exceeds manual coding accuracy (85-92%), reducing coding-related denials by 60-80% in most implementations. The impact is highest for specialties with complex coding requirements — emergency medicine, radiology, surgery — where the coding error rate is highest in manual processes.

Prior authorization denials. AI-powered authorization determination and automated submission reduce auth-related denials by 55-75% by ensuring authorization requirements are identified and fulfilled before services are rendered. The impact is highest for organizations with complex payer mixes and multi-state operations where authorization rules vary significantly.

Eligibility-related denials. AI-powered continuous eligibility monitoring reduces eligibility denials by 70-85% by detecting coverage changes between initial verification and service delivery. Real-time eligibility verification at the point of service, combined with automated re-verification before claim submission, catches the eligibility changes that manual processes miss.

AI Adoption Rate

As of early 2026, approximately 18-22% of US healthcare organizations have deployed AI-powered denial management tools. Adoption rates vary significantly by organization type:

Organization Type	AI Denial Management Adoption Rate
Large health systems (500+ beds)	38%
Community hospitals	22%
Large physician groups (50+ providers)	28%
Small practices (1-10 providers)	8%
ASCs	15%
Home health/post-acute	12%

Large health systems lead adoption, driven by the scale of their denial problem (higher absolute dollar impact justifies the investment) and the availability of technical resources for implementation. Small practices lag significantly, constrained by budget limitations and the complexity of implementing AI tools without dedicated IT support.

The adoption gap is creating a two-tier performance landscape: organizations with AI are improving their denial rates year over year, while organizations without AI are seeing their rates continue to rise with the industry trend. This divergence is expected to accelerate through 2027-2028 as AI tools become more accessible and the competitive pressure to adopt increases.

Benchmarking Your Organization

How to Calculate Your Denial Rate

Organizations often calculate denial rates inconsistently, making benchmarking difficult. The standard methodology:

Initial denial rate = (Number of claims denied on first submission) / (Total claims submitted) x 100

Key clarifications:

Include all claim types (professional, facility, outpatient, inpatient)
Count each claim line as a separate claim if tracking at the line level, or each claim as a single unit if tracking at the claim level (specify which)
Include rejections (claims that never enter adjudication due to formatting errors) — these represent operational failures that should be tracked alongside clinical denials
Measure over a rolling 12-month period to account for seasonal variation

Final denial rate = (Number of claims denied after all appeals and corrections) / (Total claims submitted) x 100

The difference between initial and final denial rate measures your organization's denial recovery effectiveness. An organization with a 13% initial denial rate and a 5% final denial rate recovers 62% of its denied claims — roughly at the industry average.

Performance Tiers

Based on the benchmarking data, organizations can classify their denial performance:

Best in class (initial denial rate below 6%). These organizations have implemented comprehensive pre-submission validation, real-time eligibility verification, automated prior authorization, and AI-powered coding. They are typically large health systems or multi-specialty groups with significant technology investment. Their denial management teams focus on complex exceptions rather than preventable errors.

Above average (6-10%). Organizations in this range have implemented electronic claims scrubbing and basic denial analytics but have not deployed AI-powered prediction or comprehensive automation. They have room for significant improvement, particularly in prior authorization automation and pre-submission denial prediction.

Average (10-14%). The majority of healthcare organizations fall in this range. They have standard billing technology and reactive denial management processes. Improvement requires both technology investment and operational redesign.

Below average (14-18%). Organizations in this range typically have understaffed billing departments, outdated technology, limited denial analytics, and reactive management processes. They are losing significant revenue to preventable denials and face cash flow pressure that constrains their ability to invest in improvement.

Critical (above 18%). Organizations above 18% initial denial rate face a financial sustainability risk. At these levels, denial management costs consume a disproportionate share of revenue cycle resources, cash flow is chronically pressured, and write-offs may threaten operational viability.

Recommendations: Reducing Denial Rates in 2026

For Organizations Above 14% Initial Denial Rate

Priority 1: Eligibility verification automation. Eligibility denials are the largest category and the most automatable. Implementing real-time eligibility verification at scheduling, registration, and pre-claim submission — with automated re-verification for any coverage changes — can reduce eligibility denials by 70-85% within 90 days.

Priority 2: Claims scrubbing enhancement. Implementing comprehensive pre-submission edits — including payer-specific rules, NCCI bundling edits, and modifier validation — addresses the coding-related and bundling-related denials that represent approximately 17% of all denials.

Priority 3: Prior authorization workflow redesign. Organizations with high auth-related denial rates should evaluate AI-powered authorization determination and automated submission tools. The ROI case is typically strong: auth-related denials are expensive, difficult to appeal, and highly preventable with the right technology.

For Organizations at 10-14% (Industry Average)

Priority 1: AI-powered denial prediction. Moving from reactive denial management to pre-submission prediction addresses the root cause. Pre-submission corrections cost 80-90% less than post-denial appeals and recover revenue weeks faster.

Priority 2: Payer-specific intelligence. Generic edits catch generic errors. The denials in the 10-14% range are increasingly payer-specific — driven by individual payer policies, clinical editing algorithms, and authorization requirements that generic systems don't address.

Priority 3: Denial analytics and root cause analysis. Organizations in this range often lack the analytics capability to identify systemic denial patterns. Implementing denial analytics that track denial rates by payer, reason, provider, service type, and time period enables targeted intervention rather than broad-brush process changes.

For Organizations Below 10%

Priority 1: Continuous model optimization. Organizations that have already deployed AI denial management should focus on continuous learning — feeding denial outcomes back into prediction models to improve accuracy over time. The difference between a 9% and a 5% denial rate is often found in model refinement rather than new technology deployment.

Priority 2: Underpayment detection. At lower denial rates, the next significant revenue opportunity often shifts from denied claims to underpaid claims — payments accepted below contracted rates. Automated payment-to-contract comparison identifies revenue that is collected but below what is owed.

Priority 3: Upstream documentation improvement. The hardest denials to prevent are those caused by insufficient clinical documentation — where the service was medically necessary but the documentation doesn't support it. Clinical documentation improvement (CDI) programs, particularly AI-powered prospective CDI, address denials at their root cause rather than at the billing stage.

Conclusion: The Denial Rate Divide

The healthcare industry is splitting into two groups: organizations that are reducing denial rates through AI-powered automation, and organizations that are watching denial rates continue to climb. The data is clear on where each trajectory leads.

Organizations in the first group are operating at 5-8% denial rates, resolving remaining denials in days rather than weeks, and redeploying denial management staff to higher-value work. Their revenue cycles are predictable, their cash flow is stable, and their administrative costs are declining as a percentage of revenue.

Organizations in the second group are managing 13-18% denial rates with understaffed teams, writing off millions in recoverable revenue, and spending an increasing share of their operating budgets on administrative rework. Their revenue cycles are volatile, their cash flow is pressured, and their best billing staff are leaving for organizations that have invested in better tools.

The gap will continue to widen. AI denial management tools are becoming more accurate, more affordable, and more accessible. Organizations that adopt early are building data advantages — their AI models are learning from more denial outcomes, becoming more accurate, and delivering compounding returns. Organizations that delay will find the gap increasingly difficult to close.

The question for healthcare leaders in 2026 is no longer whether AI denial management works. The data answers that definitively. The question is how quickly their organizations can move from the second group to the first.

Frequently Asked Questions

What is the average healthcare claim denial rate in 2026?

The industry-wide initial-denial rate is running at roughly 12.6% in 2026. Top-quartile organizations operate at 5–8%, while the bottom quartile is pushing 15–18%. Denial rates have risen every year since 2020 due to payer policy complexity, prior authorization expansion, and staffing shortages. National averages reported by CMS, HFMA, and MGMA diverge because each applies different inclusion rules — CMS counts only fee-for-service Medicare; HFMA MAP Keys and MGMA DataDive report across all payers.

Which payer has the highest denial rate?

Denial rates vary by payer, plan line, and geography. Medicare Advantage plans generally report higher initial denial rates than traditional fee-for-service Medicare, driven primarily by prior authorization requirements. Among commercial payers, large national plans tend to have higher CARC 197 (missing precertification) volumes because their PA lists are broader. The single most reliable comparison is same-code / same-geography: compare CARC volumes by CPT code + payer, not total denial rates.

What are the top CARC codes in 2026?

Three codes dominate 2026 denial volume: CARC 197 (precertification / authorization absent), CARC 11 (diagnosis inconsistent with procedure), and CARC 16 (claim lacks information). Together these account for more than half of all denied claim dollars. CARC 45 (charge exceeds fee schedule), CARC 29 (time limit expired), and CARC 96 (non-covered charge) round out the top six. CARC code definitions are maintained by the X12 Claim Adjustment Reason Code (CARC) committee.

How much does a single claim denial cost to rework?

Industry benchmarks from HFMA and MGMA put the fully loaded cost of reworking a single denied claim at $25–$117 depending on complexity. A simple documentation resubmission costs $25–$40; a clinical appeal with medical director review runs $80–$117. Approximately 35% of initial denials are never reworked and become write-offs — representing the single largest recoverable revenue line item for most healthcare organizations.

How do AI denial management tools reduce denial rates?

AI tools reduce denials across three pressure points: front-end prevention (identifying coding, eligibility, or authorization gaps before submission), automated work-queue routing (ranking denials by recoverability and urgency so staff work the highest-value cases first), and appeal assembly (drafting evidence-linked appeal letters using the denial reason and the patient's clinical record). Organizations with mature AI-first denial programs consistently operate 30–50% below peer denial rates.

This benchmark report compiles data from published industry sources, government data, and aggregate analysis. Specific figures represent industry estimates based on available data; individual organizational performance varies. QuickIntell's AI-powered denial management platform helps organizations achieve top-quartile denial performance. Contact us for a denial rate analysis specific to your organization.